๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Clustering in the incidence of myelodysplastic syndromes

โœ Scribed by Xiaomei Ma; Steve Selvin; Azra Raza; Kathryn Foti; Susan T. Mayne


Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
668 KB
Volume
31
Category
Article
ISSN
0145-2126

No coin nor oath required. For personal study only.

โœฆ Synopsis


The myelodysplastic syndromes (MDS) are a group of malignancies with poor prognosis and obscure etiology. To better understand the distribution of MDS in the population and help generate etiologic hypotheses, we assessed potential clustering in the incidence of MDS in the state of Connecticut using population-based cancer registry data that recently became available. A significant spatial clustering was identified. The most likely area with a high incidence of MDS included 46 census tracts near the west border of Connecticut, and the ratio of observed/expected cases was 2.84. The P value associated with this cluster was 0.0001. Although no temporal clustering was indicated, a space-time analysis identified a cluster in the central south of Connecticut from March 2002 through August 2003 (P=0.008). This is the first analysis of potential clustering in the incidence of MDS using population-based data. If the intriguing finding on spatial clustering is supported by future studies with larger sample sizes and/or in other geographic areas, it would be extremely interesting to explore the "causes" of clustering, which may help shed light on the etiology of MDS.


๐Ÿ“œ SIMILAR VOLUMES


The incidence and impact of thrombocytop
โœ Hagop Kantarjian; Francis Giles; Alan List; Roger Lyons; Mikkael A. Sekeres; She ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 125 KB

## Abstract Thrombocytopenia and platelet dysfunction contribute to hemorrhagic complications in the myelodysplastic syndromes (MDS). Reliable data regarding the frequency and consequences of thrombocytopenia in MDS are lacking. An extensive literature review indicated that the prevalence of thromb

Myelodysplastic syndromes : Incidence an
โœ Xiaomei Ma; Monique Does; Azra Raza; Susan T. Mayne ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 133 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND. Myelodysplastic syndromes (MDS) became reportable to the Surveillance, Epidemiology, and End Results (SEER) Program (the United States cancer surveillance program) in 2001. This provided the first opportunity to examine the incidence and survival of patients with MDS in

The treatment of the myelodysplastic syn
โœ Harvey D. Preisler ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 67 KB ๐Ÿ‘ 2 views

T he article by Ferrara et al. 1 in this issue of Cancer describes the treatment of patients with poor prognosis myelodysplastic syndromes (MDS) using intensive remission induction chemotherapy followed by peripheral blood stem cell transplantation for patients age ฯฝ 60 years. Thirty-two patients wi

Impact of iron overload in myelodysplast
โœ Pierre Fenaux; Christian Rose ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 128 KB

Anaemia is prevalent in patients with myelodysplastic syndromes (MDS), and most patients with MDS receive regular red blood cell transfusions, which can lead to iron overload. Some patients may already have iron overload before transfusions begin, as a result of ineffective erythropoiesis. Iron over